The key to your success

GlaxoSmithKline has started enrollment for phase III trials for its herpes zoster vaccine for the prevention of shingles.

This post was written by Hanson Search on August 27, 2010
Posted Under: Uncategorised

The trials will study more than 30,000 patients globally and will evaluate the efficacy, safety and immunogenicity of the candidate vaccine.

Merck’s Zostavax was the first approval of a shingles vaccine and came onto the market in 2006. 

 By Saphia Haddouche

Add a Comment



required, use real name

required, will not be published



optional, your blog address

Previous Post: